key: cord-0811378-mg38gbu5 authors: Li, Pu-Yu; Li, San-Qiang; Gao, She-Gan; Dong, Dao-Yin title: A one-step platform for screening high-efficient and minimal off-target CRISPR/Cas13 crRNAs to eradicate SARS-CoV-2 virus for treatment of COVID-19 patients date: 2022-01-04 journal: Med Hypotheses DOI: 10.1016/j.mehy.2021.110754 sha: 9e596e3c5c979e2cbdf9ebfa5f234d3efe584911 doc_id: 811378 cord_uid: mg38gbu5 Coronavirus disease 2019 (COVID-19) is a new respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and now spreads globally. Currently, therapeutics and effective treatment options remain scarce and there is no proven drug to treat COVID-19. Targeting the positive-sense RNA genome and viral mRNAs of SARS-CoV-2 to simultaneously degrade viral genome templates for replication and viral mRNAs for essential gene expression would be a strategy to completely realize virus elimination. Type VI CRISPR enzymes Cas13 have recently been identified as programmable RNA-guided, RNA-targeting Cas proteins with nuclease activity that allows for RNA cleavage and degradation. The precise viral RNA detection and antiviral application of the CRISPR/Cas13 system depend on high-efficient and minimal off-target crRNAs. Although a computer-based algorithm has been applied for the design of crRNAs targeting SRAS-CoV-2, the experimental screening system to identify optimal crRNA is not available. We develop a one-step experimental screening system to identify high-efficient crRNAs with minimal off-target effects for CRISPR/Cas13-based SARS-CoV-2 elimination. This platform provides the foundation for CRISPR/Cas13-based diagnostics and therapeutics for COVID-19. This platform is versatile and could also be applied for crRNAs screening for other RNA viruses. Coronavirus disease 2019 (COVID-19) is a new respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and now spreads globally [1, 2] . SARS-CoV-2 is classified in the Coronaviridae family and betacoronavirus genus and the seventh coronavirus known to infect humans and it is an enveloped, positive-sense, single-stranded RNA virus with mammalian and avian hosts [3] . The SARS-CoV-2 virus enters the human cell, releases its RNA genome into the cytoplasm, and synthesizes negative-sense RNA intermediates which serve as the templates for the synthesis of sub-genomic RNAs and positive-sense viral genome for new virus production [4] . A critical feature of SARS-CoV-2 is the fast transmission by human-tohuman contact, or by touching surfaces contaminated by the infected person, or by breathing aerosol that quickly led to a worldwide public health emergency [5] . The clinical spectrum of SARS-CoV-2 infection ranges from asymptomatic infection to fatal disease [5] . Some people may suffer from fever, cough, fatigue, shortness of breath, occasionally watery diarrhea, or worsened symptoms such as pneumonia, acute respiratory distress syndrome, and death, which resulted in serious public and healthcare-related casualties worldwide [5] . Unfortunately, therapeutics and effective treatment options remain scarce and there is no proven drug to treat COVID-19 [6] . To combat the SARS-CoV-2 virus, many drugs are repurposed to treat COVID-19 by targeting the SARS-CoV-2 virus, such as chloroquine, hydroxychloroquine, lopinavir/ritonavir, and ribavirin [7] . Immunomodulatory drugs such as IL-6 inhibitors (eg, sarilumab or tocilizumab) or anti-GM-CSF compounds (eg, lenzilumab and gimsilumab) are clinically tested to prevent or reverse SARS-CoV-2-caused pneumonia and acute respiratory distress syndrome [8] . In addition, various novel drugs are developed to inhibit SARS-CoV-2 virus replication and infection [9] . Prasad et al found annonaceous acetogenins showed a good inhibition activity against the SARS-CoV-2 spike protein through computational approaches [10] . Nevertheless, these drugs are designed to inhibit the replication and infection of SARS-CoV-2 but not eliminate it in the infected lung. Moreover, we do not yet know which drugs would be showed effective against SARS-CoV-2. The devastating impact of the SARS-CoV-2 pandemic on society and economics emphasizes an unprecedentedly urgent need to find effective drugs to reduce the clinical consequence of COVID- Type VI CRISPR (clustered regularly interspaced short palindromic repeats) enzymes Cas13 have recently been identified as programmable RNA-guided, RNA-targeting Cas proteins with nuclease activity that allows for RNA cleavage and degradation [11] [12] [13] [14] [15] [16] . Cas13 proteins are guided to the target RNA by a single CRISPR RNA (crRNA) composed of a direct repeat (DR) stem-loop and a spacer sequence (gRNA) that mediates target recognition by RNA-RNA hybridization and then causes targeted RNA cleavage and degradation. CRISPR/Cas13-based methods have been developed for COVID-19 diagnosis (SHERLOCK and CREST) and therapeutics (PAC-MAN and ABACAS) [17] . CRISPR/Cas13-based diagnostic platforms seem rapid, sensitive, and specific for the detection of SARS-CoV-2, but their efficiency in clinical use remains unknown [17] . The major shortcoming of these methods is the off-target effects that led to the poor signaling and misinterpretation of results [17] . CRISPR/Cas13-based therapeutic platforms are more dependent on the high specificity and low off-target effects for clinical use [18] . To improve the specificity and avoid the off-target effects of CRISPR/Cas13 system, we need to design high-efficient and minimal off-target crRNAs. A computer-based algorithm has been developed for the design of crRNAs to target SRAS-CoV-2 [19] . However, sequence analysis by GUIDE-seq revealed that many off-target sites cannot be predicted by in silico methods [20] . It implies that crRNA design cannot completely depend on the computer-based algorithms and the experimental screening system to identify optimal crRNA is necessary. So far, there is no such experimental crRNA screening system to be reported. We hypothesize that targeting the positive-sense RNA genome and viral mRNAs of SARS-CoV-2 by CRISPR/Cas13 system to simultaneously degrade viral genome templates for replication and viral mRNAs for essential gene expression would be a strategy to completely realize SARS-CoV-19 virus elimination. To reach this purpose, we develop a one-step experimental screening system to identify high-efficient crRNAs with minimal off-target for CRISPR/Cas13-based SARS-CoV-2 elimination. This platform provides the foundation for CRISPR/Cas13-based diagnostics and therapeutics for COVID-19. This platform is versatile and could also be applied for crRNAs screening for other RNA viruses. Experimental procedure 1. The design of crRNAs targeting SARS-CoV-2. Theoretically, Cas13 can target anywhere of the RNA sequence because no protospacer flanking sequence (PFS) restriction has been documented for the Cas13 orthologs, including Cas13a, Cas13b, and Cas13d, in mammalian cells [11, 12, 14, 16] . Because there is no available SARS-CoV-2 virus strain for conventional laboratory application, a conserved genomic region coding the RNA-dependent RNA polymerase (RdRp) is selected as the target sequence to design crRNAs for one-step platform assessment. RdRp is an essential gene for viral replication and conserved among human coronaviruses and a versatile drug target for anti-coronavirus [21] [22] [23] [24] . Sequence alignment analysis demonstrated that the genomic region of SARS-CoV-2 RdRp is rarely mutated among COVID-19 patients ( Figure 1 ). In addition, there is no the similar sequence in the human transcriptome except a 19-nt sequence (CCTGTTGTAGATTCTTATT) that localizing in the KMT2C mRNA. Therefore, the RdRp is an ideal target for designing crRNAs. Considering that the secondary structure of RNA will reduce the efficiency of the CRISPR/Cas13 system, the RNAxs platform is used to find regions of SARS-CoV-2 RdRp that have good accessibility for crRNAs [25] . The CRISPR library is constructed according to a protocol from Wessels et al [19] . The guide RNA, including single-guide RNA (sgRNA) for CRISPR/Cas9 system and CRISPR RNA (crRNA) for the CRISPR/Cas13 system, is a key component of CRISPR/Cas system because the quality of guide RNA is critical for the efficacy and specificity of CRISPR/Casmediated DNA/RNA editing [31] . Therefore, more attention is paid to design an efficient and functional guide RNA with high on-target efficacy and low off-target effects [32] . Three different computation-based genres appear for guide RNA designing: 1. pattern recognition genre; 2. feature rule genre; 3. machine learning genre [33] . In theory, the CRISPR/Cas system searches PAM sequence in genome and guide RNA recognizes target site to activate endonuclease activity to cut specific locus. However, sequence features of guide RNA, epigenetic features of the host genome, energetics features of guide RNA and the host genome affect guide RNA efficacy, which make guide RNA design become extraordinarily complex [33] . Therefore, guide RNAs need to be experimentally validated for the efficacy after designing by the software. To avoid off-target effects, in silico methods are developed to evaluate off-target sites by aligning short guide RNA sequence to reference genome to detect mismatch number [32] . However, sequence analysis by GUIDE-seq revealed that numerous off-targets with high-mismatch or even with one-mismatch cannot be predicted by sequence alignment algorithm [20] . So, off-target effects need to be validated by established methods such as CIRCLE-seq [34] , GUIDE-seq [20] , DISCOVER-seq [35] , and Digenome-seq [36] . This one-step guide RNA screening platform is a combination of CRISPR screening and single-cell RNA sequencing and is the first method for simultaneously screening guide RNAs with high on-target efficacy and low off-target effects. RdRp is selected as a target to design crRNA for the application of CRISPR/Cas13-based therapeutics based on several reasons: 1) RdRp is a versatile enzyme for viral RNA replication and transcription of viral genome in host cells, which makes RdRp essential for viral survival and spread [3, 24] ; 2) RdRp is considered to be a highly conserved enzyme across all RNA viruses and some DNA viruses, such as coronavirus, influenza virus, zika virus, hepatitis C virus [37] ; 3) RdRp has a very low mutation rate among COVID-19 patients ( Figure 1 ); 4) RdRp has no homologs in human cells and its RNA sequence shows an extremely low similarity with human transcriptome [38] ; 5) The essential role of RdRp for viral RNA replication and transcription makes it become a promising therapeutic target and many drugs are repurposed and developed to target it for COVID-19 treatment, such as remdesivir [22] , favipiravir [39] , ribavirin [40] , sofosbuvir [41] , and galidesivir [42] . We develop a one-step experimental screening platform to identify high-efficient and selective crRNAs with minimal off-target effects for therapeutic eradication of SARS-CoV-2 virus in vivo laying a foundation for effective treatment of COVID-19. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. COVID-19: towards controlling of a pandemic The COVID-19 pandemic in the USA: what might we expect? SnapShot: COVID-19 The Architecture of SARS-CoV-2 Transcriptome Epidemiology and pathobiology of SARS-CoV-2 (COVID-19) in comparison with SARS, MERS: An updated overview of current knowledge and future perspectives Covid-19 -The Search for Effective Therapy Treatment for COVID-19: An overview Novel Drugs Targeting the SARS-CoV-2/COVID-19 Evaluation of Annona muricata Acetogenins as Potential Anti-SARS-CoV-2 Agents Through Computational Approaches. Front Chem 2020 RNA targeting with CRISPR-Cas13 C2c2 is a single-component programmable RNAguided RNA-targeting CRISPR effector RNA editing with CRISPR-Cas13 Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors Cas13b Is a Type VI-B CRISPR-Associated RNA-Guided RNase Differentially Regulated by Accessory Proteins Csx27 and Csx28 CRISPR systems: Novel approaches for detection and combating COVID-19 CRISPR vs COVID-19: how can gene editing help beat a virus? Massively parallel Cas13 screens reveal principles for guide RNA design GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus Structural Basis for the Inhibition of the RNA-Dependent RNA Polymerase from SARSCoV-2 by Remdesivir The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase Structure of the RNA-dependent RNA polymerase from COVID-19 virus The impact of target site accessibility on the design of effective siRNAs Cas13d Is a Compact RNA-Targeting Type VI CRISPR Effector Positively Modulated by a WYL-Domain-Containing Accessory Protein Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 AAV vector distribution in the mouse respiratory tract following four different methods of administration Design and analysis of CRISPR-Cas experiments Computational approaches for effective CRISPR guide RNA design and evaluation silico Method in CRISPR/Cas System: An Expedite and Powerful Booster CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets Unbiased detection of CRISPR off-targets in vivo using DISCOVER-Seq Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells RNA Dependent RNA Polymerases: Insights from Structure, Function and Evolution RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19 Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trial In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase This research was funded by the National Natural Science Foundation of China (grant number: The authors declare no conflicts of interest. The study was approved by the Institutional Review Board of the University of Henan University of Science and Technology (HUST).